Nidovirales infectious disease
MONDO:0005876Infections with viruses of the order nidovirales. The concept includes arterivirus infections and coronaviridae infections.
Also known as: Nidovirales caused disease or disorder, Nidovirales disease or disorder
978 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
Nasal spray vaccine aims to stop COVID-19 at the source
Vaccine Not yet recruitingThis study tests a new type of COVID-19 booster vaccine given as a nasal spray. The vaccine uses a weakened live virus to train the immune system, potentially offering stronger protection in the nose and throat where the virus enters. Researchers are enrolling 80 healthy adults a…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 06, 2026 00:00 UTC
-
Can updated COVID-19 shots better protect High-Risk groups?
Vaccine Not yet recruitingThis Phase 3 trial tests updated versions of the BNT162b2 COVID-19 vaccine in adults and children aged 5 and older. Participants include those aged 5 to 64 with medical conditions that raise their risk of severe COVID-19, as well as everyone aged 65 and older. The study compares …
Phase 3 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
-
Can a Self-Amplifying RNA vaccine outsmart the latest COVID variant?
Vaccine Not yet recruitingThis early-stage trial tests a new vaccine called BMI2012, designed to protect against the Omicron JN.1 variant of COVID-19. Healthy adults aged 19 to 55 receive a single injection of either the vaccine or a placebo. Researchers will check how safe the vaccine is and whether it t…
Phase 1 • Sponsor: BMI Korea • Aim: Vaccine
Last updated Aug 30, 2026 00:00 UTC
-
Brazil tests homegrown mRNA booster against COVID-19
Vaccine Not yet recruitingThis early-stage trial tests a new mRNA COVID-19 booster vaccine made by Bio-Manguinhos/Fiocruz. About 90 healthy adults aged 18-59 will receive one of three doses (25, 50, or 100 micrograms) to check safety and immune response. The study is not yet recruiting and will monitor pa…
Phase 1 • Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) • Aim: Vaccine
Last updated Jun 27, 2026 13:06 UTC
-
New Self-Amplifying mRNA vaccine aims to better protect transplant patients against COVID-19
Vaccine Not yet recruitingThis study tests a new COVID-19 vaccine (LUNAR-COV19) in 56 adults who received a blood stem cell transplant within the past year. These patients often have weaker immune responses to standard vaccines. The new vaccine uses a self-amplifying mRNA that may produce a stronger and l…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Vaccine
Last updated Jun 27, 2026 09:04 UTC
-
Could a common diabetes pill ease long COVID?
Disease control Not yet recruitingThis Phase 3 trial tests whether dapagliflozin, a drug used for diabetes, can improve quality of life in people with long COVID. 192 adults with persistent symptoms for at least 12 weeks after a COVID infection will receive either the drug or a placebo daily for 12 months. The ma…
Phase 3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a simple steroid course save lives in severe respiratory infections?
Disease control Not yet recruitingThis study tests whether giving a 7-day course of corticosteroids (like prednisolone) to hospitalized adults with severe respiratory infections and low oxygen levels can reduce deaths and the need for breathing machines. About 3,000 participants will be randomly assigned to recei…
Phase 4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug AVM0703 tested for Life-Threatening lung failure
Disease control Not yet recruitingThis early-stage study tests a single dose of a new drug called AVM0703 in 16 adults with severe breathing failure (ARDS) caused by COVID-19 or the flu. The main goal is to check if the drug is safe and how the body processes it. Participants are randomly assigned to receive the …
Phase 1 • Sponsor: AVM Biotechnology Inc • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New antibody drug aims to tackle COVID-19 early
Disease control Not yet recruitingThis early-stage trial tests a new drug called B10-FC, which is a lab-made antibody designed to fight the SARS-CoV-2 virus. The study will first give the drug to 25 healthy volunteers in increasing doses to check safety, then to 10 COVID-19 patients. The main goal is to see if th…
Phase 1 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Disease control
Last updated Jun 26, 2026 13:33 UTC
-
Can a digital swab test tell COVID and flu apart at home?
Diagnosis Not yet recruitingThis study evaluates a new digital test that people can use at home to detect COVID-19 and influenza A and B from a nasal swab. Participants with symptoms will use the test themselves and compare the results to a standard lab PCR test. The goal is to see if the test is accurate e…
Sponsor: Biocrucible Ltd • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
New At-Home test could detect flu and COVID in minutes
Diagnosis Not yet recruitingThis study will test a new at-home rapid test that checks for flu A, flu B, and COVID-19 using a nasal swab. About 200 people with symptoms will use the test themselves, and their results will be compared to standard lab PCR tests. The goal is to see if the test is accurate and e…
Sponsor: CorDx, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
Breath sniff test could spot COVID and flu in hospital patients
Diagnosis Not yet recruitingThis study tests whether analyzing chemicals in a person's breath can quickly identify serious respiratory infections like COVID-19, flu, and Legionella in hospitalized patients. Researchers will collect breath samples from 777 adults using a simple bag, then analyze them in a la…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
Breathalyzer could replace PCR for respiratory infections
Diagnosis Not yet recruitingThis study aims to see if analyzing chemicals in a person's breath can rapidly detect respiratory infections like COVID-19 or the flu. Researchers will collect breath samples from 1,665 adults with symptoms and healthy volunteers. If successful, this non-invasive test could offer…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Could a single At-Home swab detect COVID, flu, and RSV?
Diagnosis Not yet recruitingThis study will test a new at-home diagnostic test that aims to detect five respiratory viruses—COVID-19, influenza A and B, RSV, and rhinovirus—from a single nose swab. About 2,000 people with cold or flu symptoms will provide samples in simulated home environments. The test's a…
Sponsor: Aptitude Medical Systems • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
One shot for two threats: can a single vaccine stop flu and COVID?
Prevention Not yet recruitingThis trial tests whether a single combined mRNA vaccine, mCombriax (mRNA-1083), can protect adults aged 65 and older against both influenza and COVID-19 as effectively as getting two separate shots on the same day. Researchers will compare how many participants in each group deve…
Phase 4 • Sponsor: Tor Biering-Sørensen • Aim: Prevention
Last updated Aug 29, 2026 00:00 UTC
-
Could a light device stop COVID and flu? new trial aims to find out.
Prevention Not yet recruitingThis trial tests a handheld light device (RD-X19) to see if using it for 5 minutes every other day can prevent upper respiratory infections like COVID-19 and flu. It involves 130 military personnel and their families at a single base. Half will get the real device, half a sham de…
Sponsor: David Moss • Aim: Prevention
Last updated Aug 28, 2026 00:00 UTC
-
Nasal shields aim to stop COVID and flu before they start
Prevention Not yet recruitingThis study tests two nasal protective devices (Noseguard and Noseguard Night) in 2000 adults to see if they can reduce the risk of catching respiratory infections like COVID-19 and influenza. Participants will use the devices as directed for 8 weeks, and researchers will track in…
Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Prevention
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug keytruda tested as possible treatment for long COVID brain fog
Symptom relief Not yet recruitingThis early-stage trial tests whether a single dose of pembrolizumab (Keytruda), a drug used for cancer, can safely reduce long-term neurological symptoms like brain fog and dizziness in people with long COVID. Fifteen adults who had COVID-19 at least six months ago and still have…
Phase 1 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Symptom relief
Last updated Sep 09, 2026 17:00 UTC
-
Can a smartphone app heal the hidden wounds of the ICU?
Symptom relief Not yet recruitingThis study tests a mobile mindfulness program called Lift for people who survived a serious illness in the ICU and now struggle with depression, anxiety, or stress. About 450 adults will use either the Lift app or a health education app for 6 months. The goal is to see if the min…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Could placental stem cell vesicles ease COVID-19?
Symptom relief Not yet recruitingThis early-stage trial tests a single IV dose of placental stem cell vesicles (XoGlo Pro) against placebo in 64 adults with mild to moderate COVID-19. The main goal is safety, with a secondary focus on how quickly symptoms resolve. Researchers aim to see if these tiny cell partic…
Phase 1/2 • Sponsor: Kimera Labs Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New allergy shot under safety spotlight
Symptom relief Not yet recruitingThis study will test the safety of a new biologic drug called stapokibart, given as a shot, in 400 adults with seasonal allergic rhinitis (SAR). Participants are already prescribed the drug by their doctor. The main goal is to track any side effects. This is an open-label study, …
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
VR headsets take on pandemic PTSD
Symptom relief Not yet recruitingThis study tests whether virtual reality (VR) can help people cope with trauma from COVID-19. It involves 100 adults, including healthcare workers and COVID-19 survivors, who will try VR exposure therapy in 5 weekly sessions. The goal is to see if this approach reduces PTSD sympt…
Sponsor: Soonchunhyang University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Can a zap of electricity cure long COVID? new trial aims to find out
Symptom relief Not yet recruitingThis study tests whether a non-invasive device that gently stimulates nerves can help people with long COVID symptoms like muscle pain, breathing issues, and loss of taste or smell. About 104 adults who had COVID-19 and still have symptoms for at least 30 days will receive either…
Sponsor: Clinica Gema Leon • Aim: Symptom relief
Last updated Jun 26, 2026 18:27 UTC
-
Five years on: how does long COVID evolve?
Knowledge-focused Not yet recruitingThis study follows people who had COVID-19 to see how long-term symptoms, known as long COVID, change over five years. Researchers will interview participants and assess their physical, mental, and cognitive health to understand the lasting impact of the infection. The goal is to…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can our genes and gut explain long COVID?
Knowledge-focused Not yet recruitingThis observational study aims to uncover the biological mechanisms behind long COVID by comparing adults with long COVID, those who fully recovered from COVID-19, and healthy controls. Researchers will analyze blood and, when available, intestinal tissue to examine gene activity,…
Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New brain scan probes lingering COVID mysteries
Knowledge-focused Not yet recruitingThis study uses a special PET scan to look for signs of inflammation in the brains of people with Post-COVID syndrome. Researchers want to learn more about why some people have long-lasting symptoms after a COVID-19 infection. Ten Mayo Clinic patients who had COVID-19 and are exp…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
New study tracks immune clues in seniors with flu, RSV, and COVID-19
Knowledge-focused Not yet recruitingThis study follows 150 adults aged 60 and older who have a respiratory infection (flu, RSV, or COVID-19) or who test negative. Researchers will measure specific immune markers in the blood over 60 days to see how they change from early infection to recovery. The goal is to better…
Sponsor: Fabiana Sherine Ganem dos Santos • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Pandemic babies: did lockdowns shape preterm infant brains?
Knowledge-focused Not yet recruitingThis study looks at 120 preterm infants born before 34 weeks to see if those born during the COVID-19 pandemic (2020-2021) develop differently than those born after (2023-2024). Researchers will test thinking, movement, and language skills using play-based assessments. The goal i…
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
COVID-19 ECMO patients face bleeding and clot risks, new study investigates
Knowledge-focused Not yet recruitingThis study looks back at the medical records of 50 adult ICU patients with COVID-19 who needed a life-support machine called ECMO. The goal is to understand how often bleeding and dangerous blood clots happen, and how blood transfusions and blood thinners affect their care. The f…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Bus drivers to watch health video in new study
Knowledge-focused Not yet recruitingThis study will test if a new health awareness video can teach public transportation drivers in Lebanon about preventing respiratory infections like colds and flu. About 160 drivers will be split into two groups: one watches the health video, the other watches a neutral video abo…
Sponsor: Lebanese American University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New imaging technique may reveal hidden lung issues in long COVID patients
Knowledge-focused Not yet recruitingThis study will use a non-invasive imaging method called electrical impedance tomography (EIT) to measure how air moves through the lungs of 50 people with ongoing symptoms after COVID-19. Researchers will compare EIT results with standard CT scans and lung function tests to see …
Sponsor: Jan-Christoph Lewejohann • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
COVID-19 may worsen radiation side effects in breast cancer patients
Knowledge-focused Not yet recruitingThis study examines whether having COVID-19 increases the chance of lung inflammation (radiation pneumonitis) in breast cancer patients receiving radiation therapy. Researchers will review medical records of 200 patients to compare outcomes between those who had COVID-19 and thos…
Sponsor: Zhejiang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New study to see if antivirals help immunocompromised COVID patients
Knowledge-focused Not yet recruitingThis study will review medical records of 300 immunocompromised adults hospitalized with COVID-19 in France between June 2023 and April 2024. Researchers want to see how well antiviral drugs like nirmatrelvir/ritonavir and remdesivir work in these patients. The goal is to track t…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:31 UTC
-
A phase 2, randomized, Observer-Blind, dose ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1283 in participants ≥6 months to <12 years of age
Not yet recruitingThis study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to \<12 years to determine the optimal dose level per age group.
Phase 2 • Sponsor: ModernaTX, Inc.
Last updated Sep 09, 2026 17:00 UTC